Rosacea and small intestinal bacterial overgrowth: Prevalence and response to rifaximin - 18/04/13
This investigator-designed study was partly funded by Salix Pharmaceuticals Inc, including editorial assistance provided under the direction of Dr Weinstock by MedThink SciCom. |
|
Disclosures: Dr Weinstock is on the speakers bureau for Salix Pharmaceuticals Inc and Takeda Pharmaceuticals. Drs Weinstock and Steinhoff have received funding for future rosacea research. |
Vol 68 - N° 5
P. 875-876 - mai 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?